Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Connetics Corporation (NasdaqNM:CNCT)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
July 25Conference call: Connetics Analyst Day
Location
3400 West Bayshore Road
Palo Alto, CA 94303
Phone: (650) 843-2800
Fax: (650) 843-2899
Email: ir@connetics.com
Employees (last reported count): 136
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 43%
·Over the last 6 months:
 · 2 insider buys; 15.0K shares (0.1% of insider shares)
 · 5 insider sells; 11.0K shares
·Institutional: 51% (89% of float)
(78 institutions)
·Net Inst. Buying: 2.57M shares (+14.45%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Connetics Corporation's commercial business is focused on the dermatology marketplace. The Company markets three pharmaceutical products. Its two dermatology products include Luxiq for mild to moderate scalp dermatoses, and Olux for moderate to severe scalp dermatoses. The Company also sells Ridaura, a product to treat rheumatoid arthritis. Luxiq is a foam formulation of betamethasone valerate, a mid-potency topical steroid that is prescribed for the treatment of mild to moderate steroid-responsive scalp dermatoses. Olux is a foam formulation of clobetasol propionate, a prescribed super-high-potency topical steroid. Ridaura is an oral formulation of a gold salt for the treatment of rheumatoid arthritis, a chronic autoimmune disease that results in inflammation and erosion of the joints and loss of mobility. On April 20, 2001, the Company acquired Soltec Research Pty Ltd., the drug delivery unit of F H Faulding & Co Limited, an international pharmaceutical and healthcare company.
More from Market Guide: Expanded Business Description

Financial Summary
Connetics Corp. is engaged in the development and commercialization of therapeutics to address serious diseases involving the connective tissues of the body. For the six months ended 6/01, revenues fell 34% to $16 million. Net loss before acct'g change totaled $11 million vs. an income of $1.4 million. Results reflect the absence of a milestone payment under a former collaboration agreement, expenses related to sales force expansion, and a $6 million divestiture charge.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

G. Kirk Raab, 65
Chairman, Director
--  --  
Thomas Wiggans, 49
Pres, CEO, Director
$557K$82K
John Higgins, 31
CFO, Exec. VP- Fin. and Admin.
327K256K
C. Gregory Vontz, 40
COO
325K--  
Linda Fenney, M.D.
Sr. VP, Clinical Research
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CNCTAs of 31-Aug-2001
Price and Volume
52-Week Low
on 18-Oct-2000
$4.00 
Recent Price$6.00 
52-Week High
on 5-Oct-2000
$28.75 
Beta0.99 
Daily Volume (3-month avg)176.1K
Daily Volume (10-day avg)74.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-66.8%
52-Week Change
relative to S&P500
-55.4%
Share-Related Items
Market Capitalization$179.9M
Shares Outstanding30.0M
Float17.1M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.08 
Earnings (ttm)$0.60 
Earnings (mrq)-$0.21 
Sales (ttm)$1.09 
Cash (mrq)$1.86 
Valuation Ratios
Price/Book (mrq)2.88 
Price/Earnings (ttm)9.95 
Price/Sales (ttm)5.52 
Income Statements
Sales (ttm)$32.7M
EBITDA (ttm)-$30.8M
Income available to common (ttm)$19.8M
Profitability
Profit Margin (ttm)60.6%
Operating Margin (ttm)-97.5%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)23.15%
Return on Equity (ttm)26.67%
Financial Strength
Current Ratio (mrq)4.10 
Debt/Equity (mrq)0 
Total Cash (mrq)$55.8M
Short Interest
As of 8-Aug-2001
Shares Short922.0K
Percent of Float5.4%
Shares Short
(Prior Month)
919.0K
Short Ratio5.27 
Daily Volume175.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.